Assessment of egfr/her2 dimerization by fret-flim utilizing alexa-conjugated secondary antibodies in relation to targeted therapies in cancers

Oncotarget

Volumn 2, Issue 9, 2011, Pages 728-736

  Waterhouse, Benjamin R ^a   Gijsen, Merel ^a   Barber, Paul R ^b   Tullis, Iain D C ^b   Vojnovic, Borivoj ^b   Kong, Anthony ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Dimerization; Egfr; Flim; Fret; Her (ErbB) receptors; Her2 (ErbB2)

Indexed keywords

ALEXA488; ALEXA546; ANTIBODY; DYE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONJUGATION; CONTROLLED STUDY; DIMERIZATION; FLUORESCENCE LIFETIME MICROSCOPY; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PROTEIN ANALYSIS; ANIMAL; ENZYMOLOGY; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84860350484     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.313     Document Type: Article

References (26)

1. Hoellein A, Pickhard A, von Keitz F, Schoeffmann S, Piontek G, Baumgart A, Wagenpfeil S, Peschel C, Dechow T, Bier H, Keller U. Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck. Oncotarget. 2011.
2. Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006; 1:11.
3. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in nodenegative breast carcinomas. J Clin Oncol. 1997; 15:2894-2904.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177-182.
5. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003; 8:307-325.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-1672.
7. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369:29-36.
8. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20:719-726.
9. Dienstmann R, Martinez P, Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget. 2011; 2:165-177.
10. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010; 1:497-514.
11. Murray S, Bobos M, Angouridakis N, Nikolaou A, Linardou H, Razis E, Fountzilas G. Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. J Oncol. 2010; 2010:709678.
12. Dei Tos AP EI. Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods? European Journal of Cancer. 2005; 41:1383-1392.
13. Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 2010; 8:e1000563.
14. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS ONE. 2008; 3:e2881.
15. Bei R, Budillon A, Masuelli L, Cereda V, Vitolo D, Di Gennaro E, Ripavecchia V, Palumbo C, Ionna F, Losito S, Modesti A, Kraus MH, Muraro R. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol. 2004; 204:317-325.
16. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002; 7 Suppl 4:31-39.
17. Kong A, Leboucher P, Leek R, Calleja V, Winter S, Harris A, Parker PJ, Larijani B. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res. 2006; 66:2834-2843.
18. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J. 1997; 16:1647-1655.
19. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2:127-137.
20. Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalinfixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009; 18:11-21.
21. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006; 3:995-1000.
22. Jares-Erijman EA, Jovin TM. FRET imaging. Nat Biotechnol. 2003; 21:1387-1395.
23. Hoppe A, Christensen K, Swanson JA. Fluorescence resonance energy transfer-based stoichiometry in living cells. Biophys J. 2002; 83:3652-3664.
24. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009; 28:3801-3813.
25. Laurence TA, Chromy BA. Efficient maximum likelihood estimator fitting of histograms. Nat Methods. 2010; 7:338-339.
26. Barber PR, Ameer-Beg SM, Gilbey J, Carlin LM, Keppler M, Ng TC, Vojnovic B. Multiphoton timedomain fluorescence lifetime imaging microscopy: practical application to protein-protein interactions using global analysis. J R Soc Interface. 2009; 6:doi: 10.1098/ rsif.2008.0451.focus.